Showing results (1-10 of 192) with videos related to
Sort By:
Pageof 20
Kidney International|February 21, 2013
Antineutrophil cytoplasm antibody-associated vasculitis: recent developmentsShunsuke Furuta, David R W JayneCurrent Opinion in Rheumatology|November 27, 2013
Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitisShunsuke Furuta, David JayneNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 16, 2013
Impact of rituximab trials on the treatment of ANCA-associated vasculitisFederico Alberici, David R W JayneRheumatology (Oxford, England)|December 25, 2009
Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualinOliver Flossmann, David R W JayneNephron. Clinical Practice|November 16, 2005
Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitisMaria Koukoulaki, David R W JayneAnnals of the Rheumatic Diseases|December 30, 2025
Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitisIftach Sagy, David R W JayneNature Clinical Practice. Rheumatology|July 24, 2008
Maintaining remission in a patient with vasculitisOliver Flossmann, David R W JayneKidney International|November 24, 2018
ANCA Renal Risk Score: is prediction of end-stage renal disease at baseline possible?Andreas Kronbichler, David R W JayneNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 23, 2015
Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Andreas Kronbichler, David R W JayneAnnual Review of Medicine|October 29, 2013
Anti-B cell antibody therapies for inflammatory rheumatic diseasesMikkel Faurschou, David R W JaynePageof 20